RxDoctor Payments Data

Mohammad Bukhari, DO

Family Medicine · Altoona, PANPI 1306334073

Payments from drug & device makers

$981in general payments, 2019–2025

Across 11 payments — averaging $89.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • Abbott$165
  • Alkermes, Inc.$105
  • Novo Nordisk$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$70
  • Lilly USA, LLC$70
  • plus $244 from 4 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$55,291
Medicare patients
215
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$43,794
JardianceEmpagliflozin24$24,767
TrulicityDulaglutide14$23,891
OzempicSemaglutide14$13,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,705
TradjentaLinagliptin20$8,256
Breo ElliptaFluticasone/Vilanterol13$6,720
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,278
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$1,790
Albuterol Sulfate HfaAlbuterol Sulfate65$1,788
Atorvastatin Calcium200$1,732
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,542
Duloxetine Hcl77$1,287
Losartan Potassium104$1,130
Levothyroxine Sodium161$1,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$43,79441 claims
Boehringer IngelheimJardiance, Tradjenta$50$33,02344 claims
Lilly USA, LLCTrulicity$70$23,89114 claims
GSKTrelegy Ellipta, Breo Ellipta$65$16,42524 claims
Novo NordiskOzempic$102$13,45514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →